PTC Therapeutics, Inc. Long-Term Debt
PTC Therapeutics, Inc. (PTCT) had Long-Term Debt of $535.52 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt and Lease Obligation
us-gaap:LongTermDebtNoncurrent · last filed 2026-07-30
- 2026-06-30: Long-term Debt, Excluding Current Maturities $535.52M.
- 2025-06-30: Long-term Debt, Excluding Current Maturities $286.01M.
- 2025-03-31: Long-term Debt, Excluding Current Maturities $285.71M.
- 2024-12-31: Long-term Debt, Excluding Current Maturities $285.41M.
| Period end | Long-term Debt, Excluding Current Maturities | Long-term Debt, Excluding Current Maturities as first filed |
|---|---|---|
| 2026-06-30 | $535.52M 10-Q · filed 2026-07-30 | |
| 2025-06-30 | $286.01M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $285.71M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $285.41M 10-K · filed 2026-02-19 | |
| 2024-09-30 | $285.11M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $284.81M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $284.51M 10-Q · filed 2024-04-25 | |
| 2023-12-31 | $284.21M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $573.17M 10-Q · filed 2023-10-26 | |
| 2023-06-30 | $572.64M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $572.09M 10-Q · filed 2023-04-27 | |
| 2022-12-31 | $571.72M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $282.75M 10-Q · filed 2022-10-27 | |
| 2022-06-30 | $282.46M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $282.18M 10-Q · filed 2022-05-03 | |
| 2021-12-31 | $281.89M 10-K · filed 2023-02-21 | |
| 2021-09-30 | $281.60M 10-Q · filed 2021-10-28 | |
| 2021-06-30 | $430.50M 10-Q · filed 2021-07-29 | |
| 2021-03-31 | $430.04M 10-Q · filed 2021-05-04 | |
| 2020-12-31 | $309.14M 10-K · filed 2022-02-22 | |
| 2020-09-30 | $302.97M 10-Q · filed 2020-10-29 | |
| 2020-06-30 | $297.03M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $294.57M 10-Q · filed 2020-04-30 | |
| 2019-12-31 | $293.86M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $293.15M 10-Q · filed 2019-10-30 | |
| 2019-06-30 | $135.68M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $138.47M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $141.35M 10-K · filed 2020-03-02 | |
| 2018-09-30 | $144.26M 10-Q · filed 2018-11-05 | |
| 2018-06-30 | $147.20M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $146.88M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $144.97M 10-K · filed 2019-03-01 | |
| 2017-09-30 | $143.09M 10-Q · filed 2017-11-02 | |
| 2017-06-30 | $141.24M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $99.89M 10-Q · filed 2017-05-08 | |
| 2016-12-31 | $98.22M 10-K · filed 2018-03-06 | |
| 2016-09-30 | $96.56M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $94.94M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $93.37M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $91.85M 10-K · filed 2017-03-16 | $94.61M 10-K · filed 2016-02-29 |
| 2012-12-31 | $438.81K 10-K · filed 2014-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |